Recombinant Human PRDM14 protein

PRDM14 is a transcription factor belonging to the PRDI-BF1-RIZ (PRDM) protein family, characterized by a conserved PR (PRDI-BF1-RIZ) homologous domain with potential methyltransferase activity. It plays critical roles in embryonic development, pluripotency maintenance, and germline specification. PRDM14 regulates epigenetic states by interacting with chromatin modifiers and repressing genes involved in differentiation, thereby preserving the naive pluripotency of embryonic stem cells (ESCs). Its expression is tightly controlled, with high activity in early embryos, primordial germ cells, and certain cancers, particularly germ cell tumors and aggressive malignancies like breast cancer.

Recombinant PRDM14 protein is engineered for in vitro studies to dissect its molecular mechanisms. Produced via heterologous expression systems (e.g., bacterial, insect, or mammalian cells), the recombinant form allows researchers to analyze its DNA-binding specificity, interactions with co-factors (e.g., OCT4. NANOG), and enzymatic functions. Purification methods often involve affinity tags (e.g., His-tag) for efficient isolation. Studies using recombinant PRDM14 have revealed its role in resetting epigenetic marks, such as erasing H3K9me2 and suppressing the DNA damage response during reprogramming.

Its dysregulation is linked to developmental disorders and oncogenesis, making recombinant PRDM14 a tool for drug screening or therapeutic targeting. However, challenges persist in maintaining its structural stability and post-translational modifications in vitro. Ongoing research focuses on optimizing expression systems to better mimic native protein behavior, enhancing its utility in regenerative medicine and cancer biology.